Sachdev Sidhu, PhDUniversity of TorontoToronto, Ontario, Canada 2019 Pilot Study Award Research in Focus: Novel therapies to treat ovarian cancer Targeting Ephrin receptors with antibody-drug conjugates to design novel treatments for ovarian cancer Alterations in certain proteins located on the surface of cells, known as receptor proteins, can lead to the formation of tumors. These receptor […]
Read More
Keren Levanon, MD/PhDSheba Fund for Health Service and Research2019 Pilot Study Award Microbiome profiling unveils metabolic vulnerabilities of BRCA mutated ovarian cancer Recent studies have shown that fallopian tubes and other genital track tissues that were previously thought to be sterile actually contain bacteria. These bacteria are believed to cause chronic inflammation which can lead […]
Read More
Christopher J. Kemp, PhDFred Hutchinson Cancer Research Center 2019 Sequoyah Electric Pilot Study Award Preclinical advancement of combination therapy targeting BAZ2A and EZH2 in ovarian clear cell carcinoma Ovarian cancer accounts for over 14,000 deaths in the United States every year. Although ovarian cancer has several subtypes, patients have been treated almost in the same […]
Read More
Adam R Karpf, PhDUniversity of Nebraska Medical Center 2019 Pilot Study Award Oncogenic collaboration between Cyclin E1 and FOXM1 in high-grade serous ovarian cancer High-grade serous ovarian cancer is the most common form of ovarian cancer, the most deadly gynecologic malignancy. One of the most important characteristics of HGSOC is genomic instability – when DNA […]
Read More
Lana Kandalaft, PhD University Medical School, Lausanne (CHUV)2019 Dearborn Family Pilot Study Award Development of personalized cancer vaccination strategies in ovarian cancer As ovarian cancer lacks specific symptoms, most patients are diagnosed at an advanced stage whereby treatment response is poor. One option for treatment is to activate the patient’s own immune system using individually […]
Read More
Cecil Han, PhDGeorgetown University Understanding and Targeting Mitochondrial Heterogeneity in Ovarian Cancer High grade serous ovarian cancers are very complex and variable, making them difficult to treat. One source of this variability may be in the mitochondria, a cellular component known as the “powerhouse”, of ovarian cancer cells. Studies have shown that the variability in […]
Read More
Caroline Ford, PhDUniversity of New South Wales2019 James A. Harting Pilot Study Award Research in Focus: Novel therapies to treat ovarian cancer Shock and ROR! Inhibiting ovarian cancer metastasis with targeted therapies in an organotypic model of ovarian cancer In order to improve survival in ovarian cancer, we need to further study the molecular changes at […]
Read More
Pratip K Bhattacharya, PhDM.D. Anderson Cancer Center […]
Read More